Merit Medical Systems (NASDAQ:MMSI) Price Target Raised to $105.00 at BTIG Research

Posted by Francis Steltz on Aug 1st, 2026

Merit Medical Systems (NASDAQ:MMSI – Free Report) had its price target increased by BTIG Research from $100.00 to $105.00 in a report issued on Friday, MarketBeat Ratings reports. The firm currently has a buy rating on the medical instruments supplier’s stock.

MMSI has been the subject of a number of other research reports. Piper Sandler reaffirmed an “overweight” rating on shares of Merit Medical Systems in a research report on Friday, July 10th. Canaccord Genuity Group lowered their price objective on Merit Medical Systems from $90.00 to $85.00 and set a “buy” rating on the stock in a report on Friday, May 1st. JPMorgan Chase & Co. cut their price objective on Merit Medical Systems from $95.00 to $77.00 and set an “overweight” rating on the stock in a research note on Friday, May 1st. Robert W. Baird set a $83.00 target price on Merit Medical Systems in a research report on Friday, May 1st. Finally, Needham & Company LLC raised their target price on shares of Merit Medical Systems from $90.00 to $101.00 and gave the company a “buy” rating in a research note on Friday. Eight analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, Merit Medical Systems has an average rating of “Moderate Buy” and a consensus target price of $100.30.

Get Our Latest Analysis on MMSI

Merit Medical Systems Stock Up 2.0%

Merit Medical Systems stock opened at $85.01 on Friday. The company has a current ratio of 5.08, a quick ratio of 3.46 and a debt-to-equity ratio of 0.45. Merit Medical Systems has a 1-year low of $59.74 and a 1-year high of $94.75. The firm’s fifty day simple moving average is $69.87 and its 200-day simple moving average is $71.78. The company has a market capitalization of $5.07 billion, a P/E ratio of 35.13, a P/E/G ratio of 2.59 and a beta of 0.52.

Merit Medical Systems (NASDAQ:MMSI – Get Free Report) last issued its quarterly earnings data on Thursday, July 30th. The medical instruments supplier reported $1.19 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.96 by $0.23. The firm had revenue of $418.84 million during the quarter, compared to analysts’ expectations of $405.25 million. Merit Medical Systems had a net margin of 9.22% and a return on equity of 13.97%. Merit Medical Systems’s revenue for the quarter was up 9.5% on a year-over-year basis. During the same period in the prior year, the company posted $1.01 earnings per share. Merit Medical Systems has set its FY 2026 guidance at 4.250-4.350 EPS. Sell-side analysts forecast that Merit Medical Systems will post 3.62 earnings per share for the current fiscal year.

Insider Buying and Selling at Merit Medical Systems

In other Merit Medical Systems news, Director Lynne N. Ward sold 5,000 shares of the stock in a transaction on Thursday, May 7th. The shares were sold at an average price of $62.61, for a total value of $313,050.00. Following the completion of the sale, the director directly owned 7,809 shares of the company’s stock, valued at $488,921.49. This represents a 39.04% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, insider Brian G. Lloyd purchased 2,000 shares of the firm’s stock in a transaction on Thursday, May 7th. The stock was bought at an average price of $62.62 per share, for a total transaction of $125,240.00. Following the completion of the transaction, the insider directly owned 2,000 shares in the company, valued at approximately $125,240. The trade was a ∞ increase in their ownership of the stock. The SEC filing for this purchase provides additional information. Company insiders own 0.70% of the company’s stock.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in the stock. Los Angeles Capital Management LLC bought a new stake in shares of Merit Medical Systems in the fourth quarter valued at about $25,000. Maseco LLP acquired a new stake in Merit Medical Systems during the fourth quarter worth about $26,000. Torren Management LLC bought a new position in Merit Medical Systems during the fourth quarter valued at about $38,000. Covestor Ltd increased its stake in Merit Medical Systems by 252.6% during the fourth quarter. Covestor Ltd now owns 469 shares of the medical instruments supplier’s stock valued at $41,000 after acquiring an additional 336 shares during the period. Finally, Danske Bank A S acquired a new position in Merit Medical Systems in the 3rd quarter valued at approximately $42,000. Institutional investors and hedge funds own 99.66% of the company’s stock.

Key Merit Medical Systems News

Here are the key news stories impacting Merit Medical Systems this week:

Positive Sentiment: Q2 results exceeded expectations: Merit reported revenue of $418.8 million, up 9.5% year over year and above the $405.3 million consensus estimate. Non-GAAP EPS rose 18% to $1.19, beating estimates of $0.96; GAAP operating margin also improved to 14.4% from 12.3%. Merit Medical Reports Second Quarter 2026 Results and Updates Full-Year 2026 Guidance
Positive Sentiment: 2026 guidance was raised: Management now expects full-year adjusted EPS of $4.25-$4.35, above the $3.98 analyst consensus. Broad-based product growth, revenue gains and expanding margins supported the improved outlook. MMSI Q2 Earnings, Revenues Beat Estimates; 2026 Guidance Raised
Positive Sentiment: Analyst targets moved higher: Needham raised its target to $101 and maintained a Buy rating; BTIG lifted its target to $105 and maintained Buy; and JPMorgan raised its target to $95 with an Overweight rating. These revisions indicate increased confidence in Merit’s growth and earnings trajectory. Analysts Increase Forecasts After Strong Q2 Results
Neutral Sentiment: Analyst opinion remains mixed: Wells Fargo raised its target to $83 but retained an Equal Weight rating, leaving its target below the stock’s recent trading level. Wells Fargo Raises Merit Medical Price Target
Negative Sentiment: Cash generation weakened: Year-to-date operating cash flow fell 11% to $110.0 million, while free cash flow declined 14% to $76.6 million, a potential concern despite the strong earnings performance. Merit Medical Second Quarter Results

Merit Medical Systems Company Profile

(Get Free Report)

Merit Medical Systems, Inc is a global manufacturer and marketer of a broad range of medical devices used in diagnostic and interventional procedures. The company’s product portfolio encompasses vascular access, drainage, embolotherapy, and interventional oncology devices, as well as radiofrequency ablation systems and hemostasis solutions. These products serve physicians and hospitals in critical care settings and support minimally invasive treatment options across multiple specialties, including cardiology, radiology, oncology, neurology and endoscopy.

Founded in 1987 by Fred Lampropoulos, Merit Medical Systems has grown through both organic development and targeted acquisitions to expand its technology offerings and geographic reach.